TICKERNERD
Menu
CDXSCDXSHealthcare · Biotechnology

CDXS Stock Forecast: Codexis, Inc. Price Predictions for 2026-2027

Last close, 9 Oct 2026
$1.41
+3.68% on the day

The 8 Wall Street analysts covering Codexis, Inc. hold a median 12-month price target of $5 — +254.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$148.9M
Ticker Nerd rank
62 / 100
Median analyst target
$5.00
Analysts covering
8
Revenue$14.9M−2.7% y/y
Operating income−$11.2M
Net income−$12.0M
Free cash flow−$10.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.7%
1M
−1.4%
YTD
−13.5%
1Y
−47.4%
From 52W high
−50.5%
From 52W low
+43.9%
$0.98
$2.85
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CDXS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Codexis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
62 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Accruals
85
Size
71
Quality
65
Revisions
61
Value
45
Issuance
27
Momentum
16
Volatility
11

Growth (99): Sales and profits are climbing, and climbing faster than before.

Volatility (11): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CDXS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CDXS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26CDXSHigh $11.00Median $5.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
6 Buy2 Hold0 Sell
Low $2.00Median $5.00High $11.00

The green dot is the last close — the median target sits +254.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026Piper SandlerMaintainsOverweight$9.00 → $8.00
22 Nov 2024Cantor FitzgeraldReiteratesOverweight$11
22 Nov 2024Cantor FitzgeraldReiteratesOverweight—
15 Nov 2024Cantor FitzgeraldReiteratesOverweight$11
15 Nov 2024Cantor FitzgeraldReiteratesOverweight—
4 Nov 2024BenchmarkReiteratesHold—
20 Sept 2024Cantor FitzgeraldReiteratesOverweight—
29 Aug 2024Cantor FitzgeraldReiteratesOverweight—
19 Aug 2024BenchmarkDowngradeHold—
9 Aug 2024Cantor FitzgeraldReiteratesOverweight—
30 May 2024Cantor FitzgeraldInitiatesOverweight—
3 May 2024BenchmarkReiteratesBuy—
29 Feb 2024BenchmarkUpgradeBuy—
7 Nov 2023BenchmarkDowngradeHold—
6 Nov 2023Piper SandlerMaintainsOverweight—
1 Sept 2023BenchmarkReiteratesBuy—
14 Aug 2023StifelMaintainsBuy—
21 July 2023Stephens & Co.ReiteratesOverweight—
9 May 2023BenchmarkMaintainsBuy—
9 May 2023HC Wainwright & Co.DowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CDXS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CDXS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Oct 2026, Codexis, Inc. returned −47.4% against +17.3% for the S&P 500, dividends included.

CDXS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26CDXSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CDXS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Codexis, Inc. (CDXS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.8×

Cheaper than 87% of US stocks

Price / sales
1.9×

Cheaper than 53% of US stocks

Price / book
3.8×

Cheaper than 26% of US stocks

EV / EBITDA
−8.7×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
−2.7%

Higher than 23% of US stocks

Earnings growth (YoY)
−2.7%

Higher than 33% of US stocks

Gross margin
76.5%

Higher than 88% of US stocks

Operating margin
−75.3%

Higher than 15% of US stocks

Net margin
−39.6%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−69.4%

Higher than 17% of US stocks

Return on assets
−11.7%

Higher than 25% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Codexis, Inc. (CDXS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Codexis, Inc. has a market value of $148.9M and an enterprise value of $166.6M.

  • Revenue in the twelve months to 30 June 2026: $77.7M. The latest quarter shrank 2.7% year on year.

  • Net income over the same four quarters: −$30.7M, a −39.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.34.

  • Free cash flow in the twelve months to 30 June 2026: −$12.2M.

  • Shares outstanding: 91.4M.

  • Trailing P/E: −2.8×; forward P/E: −4.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Codexis, Inc. employs 146 people — $532K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

CDXS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CDXSCodexis, Inc.$148.9M
62
TLSATiziana Life Sciences Ltd. (Bermuda)$145.0M
18
AVXLAnavex Life Sciences Corp.$142.7M
24
NERVMinerva Neurosciences, Inc.$150.0M
35
ARMPArmata Pharmaceuticals, Inc.$141.4M
74
RNAAtrium Therapeutics, Inc.$141.4M
5
VYGRVoyager Therapeutics, Inc.$141.3M
76

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Codexis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CDXS news & analysis

Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA

GlobeNewsWire · 28 Sept 2026positive

Codexis announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis Manufacturing Platform. The collaboration aims to utilize Codexis's enzymatic solutions for siRNA manufacturing.

Why it matters — The agreement could expand the application of Codexis's ECO Synthesis platform into the growing siRNA therapeutics space, potentially broadening its commercial opportunities.

Codexis to Participate in Cantor Global Healthcare Conference 2026

GlobeNewsWire · 27 Aug 2026neutral

Codexis announced it will attend the Cantor Global Healthcare Conference 2026, scheduled for September 9-11, 2026, in New York, New York. The company is a provider of enzymatic solutions for manufacturing complex therapeutics.

Why it matters — A CDXS watcher would care because the conference provides an opportunity for the company to present its enzymatic solutions to the healthcare investment community.

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research · 14 Aug 2026positive

Codexis was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Why it matters — An upgrade to Buy suggests increased positive sentiment around Codexis's near-term earnings outlook, which could influence how investors view the stock.

Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Codexis, Inc. held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covered the company's financial results and operational highlights for the quarter.

Why it matters — Earnings call transcripts provide CDXS watchers with direct insight into management's commentary on quarterly performance and strategic direction.

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 11 Aug 2026positive

Codexis reported a second-quarter loss of $0.13 per share, narrower than the Zacks Consensus Estimate of a $0.17 loss and an improvement from the $0.16 loss in the same period last year. The company also topped revenue estimates for the quarter.

Why it matters — A CDXS watcher would care because the company beat analyst expectations on both earnings and revenue, indicating better-than-anticipated quarterly performance.

FAQ

Frequently asked questions about CDXS stock

What is the CDXS stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Codexis, Inc. have a median 12-month price target of $5, with estimates ranging from $2 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CDXS stock a buy right now?

Of the 8 analysts covering Codexis, Inc., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Codexis, Inc. 62 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CDXS?

As at 8 Oct 2026, Codexis, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will CDXS stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +254.6% from the last close, and Ticker Nerd's factor model ranks Codexis, Inc. 62 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CDXS stock forecast for 2030?

No analyst covering Codexis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $11 over the next 12 months.

How has CDXS stock performed over the past year?

Codexis, Inc. returned -47.4% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Codexis, Inc. do?

Codexis Inc. is a biotechnology company focused on enzyme engineering and biocatalysis.

What is the latest news on CDXS?

The most recent item we track (GlobeNewsWire, 28 Sept 2026): "Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA". Codexis announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis Manufacturing Platform. The collaboration aims to utilize Codexis's enzymatic solutions for siRNA manufacturing.

Company

About Codexis, Inc.

Codexis Inc. is a biotechnology company focused on enzyme engineering and biocatalysis. Codexis develops and commercializes proprietary protein engineering technologies that create tailored enzymes for pharmaceutical manufacturing, RNA synthesis, molecular biology, diagnostics, and other life sciences applications. Its portfolio includes enzyme-based solutions, screening kits, and process development support designed to improve efficiency in complex manufacturing workflows. The company serves customers across the pharmaceutical, industrial, food, agricultural, and specialty chemicals markets, where engineered enzymes can help enable more precise and scalable production processes. Codexis also works on next-generation biotherapeutic and oligonucleotide manufacturing platforms, reflecting its role as a specialized provider of tools and technologies for modern drug development and advanced biological manufacturing. Headquartered in Redwood City, California, Codexis Inc. operates as a platform-driven company within the broader life sciences and synthetic biology market.

CEO Dr. Alison Moore Ph.D. · 146 employees · United States · https://www.codexis.com